Abstract:Integrase strand transfer inhibitors (INSTIs) are the most recent class of antiretroviral drugs with potent and durable antiviral activity used to treat human immunodeficiency virus type 1 (HIV-1) infection. However, development of drug resistance increases the risk of treatment failure, disease progression and mortality. A better understanding of drug efficacy and resistance against INSTIs is crucial for their efficient use and the development of new antiretrovirals. A meta-analysis of studies reporting efficacy and resistance data on INSTI use in HIV-infected patients was performed. Odds ratios (ORs) of efficacy outcome data favouring INSTI use in different clinical settings demonstrated that INSTIs have higher efficacy compared with drugs of other classes. For combination antiretroviral therapy-naïve patients and virologically-suppressed patients who switched to INSTI-based therapy, the OR was 1.484 (95% CI 1.229-1.790) and 1.341 (95% CI 0.913-1.971), respectively. ORs of resistance data indicated decreased treatment-emergent resistance development to dolutegravir (DTG) upon virological failure than to non-INSTIs (OR = 0.081, 95% CI 0.004-1.849), whereas the opposite was observed for raltegravir (RAL) (OR = 3.137, 95% CI 1.827-5.385) and elvitegravir (EVG) (OR = 1.886, 95% CI 0.569-6.252). Pooled analysis of resistance data indicated that development of resistance to DTG and bictegravir was rare, whereas EVG and RAL had low genetic barriers to resistance and the intensive cross-resistance between them limits INSTI efficiency. Efficient means of monitoring the emergence of resistance to INSTIs and the development of drugs with high genetic barriers are clear paths for future research.

Research Progress of HIV-1 Integrase and Its Inhibitors

Progress in Research on HIV-1 Integrase and Its Inhibitors

Research Progress in HIV Integrase Inhibitors

Research progress on HIV latency-reversing agents and its mechanism

Advances in the development of HIV integrase strand transfer inhibitors.

Meta-analysis and Systematic Review of the Efficacy and Resistance for Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitors.

Integrase inhibitors: current protagonists in antiretroviral therapy

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Screening and identification of inhibitors on HIV-1 integrase

Recent Progress in HIV-1 Inhibitors Targeting the Entrance Channel of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket

Inhibitors of HIV-1 Replication That Inhibit HIV Integrase.

Discovery of Inhibitors to Block Interactions of HIV-1 Integrase with Human LEDGF/p75 Via Structure-Based Virtual Screening and Bioassays.

Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

Research Progress of the Anti-HIV Activity of SAMHD1

Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Research Progress of HEPT Analogs As Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Brief Histories of Retroviral Integration Research and Associated International Conferences